Holen Sie sich die Stockscreener-App
0.591
4.07%
-0.0251
Handel nachbörslich:
.59
-0.001
-0.17%
Schlusskurs vom Vortag:
$0.6161
Offen:
$0.62
24-Stunden-Volumen:
210.97K
Relative Volume:
1.31
Marktkapitalisierung:
$11.47M
Einnahmen:
$4.03M
Nettoeinkommen (Verlust:
$24.32M
KGV:
-0.1374
EPS:
-4.3008
Netto-Cashflow:
$-45.76M
1W Leistung:
-3.89%
1M Leistung:
-3.11%
6M Leistung:
-7.66%
1J Leistung:
-16.76%
1-Tages-Spanne:
$0.571
$0.62
1-Wochen-Bereich:
$0.571
$0.628
52-Wochen-Spanne:
$0.55
$1.90
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Vergleichen Sie PAVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.591 | 11.47M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
PAVmed Holds Annual Stockholders Meeting, Approves Key Proposals - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
PAVmed (NASDAQ:PAVM) Given New $19.00 Price Target at Ascendiant Capital Markets - Defense World
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - MSN
PAVM: Ascendiant Capital Maintains Buy Rating but Lowers Price Target | PAVM Stock News - GuruFocus
PAVmed subsidiary Veris Health partners with Ohio State University cancer center - Yahoo Finance
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnersh - GuruFocus
PAVM Subsidiary Veris Health Partners with OSUCCC -- James for Cancer Care Innovations | PAVM Stock News - GuruFocus
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer CenterJames Cancer Hospital and Solove Research Institute | PAVM Sto - GuruFocus
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com UK
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification - Yahoo Finance
Pavmed Inc. Reports Turnaround with Strong Q1 Earnings - TipRanks
PAVmed Q1 2025 slides: net income soars amid strategic restructuring By Investing.com - Investing.com India
PAVmed Q1 2025 slides: net income soars amid strategic restructuring - Investing.com
Earnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shifts - Investing.com Nigeria
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Reports Q1 2025 Financial Results and Updates - TipRanks
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed (PAVM) Q1 Earnings Beat with Improved EPS and Revenue - GuruFocus
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports First Qua - GuruFocus
Lucid Diagnostics Reports Q1 2025 Financial Results - TipRanks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - StreetInsider
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Finansavisen
Transcript : Lucid Diagnostics Inc., Q1 2025 Earnings Call, May 14, 2025 - MarketScreener
PAVmed (PAVM) to Release Quarterly Earnings on Thursday - Defense World
PAVmed to Hold a Business Update Conference Call and Webcast on - GuruFocus
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - The Victoria Advocate
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 | PAVM Stock News - GuruFocus
PAVmed Sets Key Q1 2025 Earnings Call: MedTech Growth Strategy and Financial Results Coming May 15 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
PAVmed switches to new accounting firm post-acquisition - Investing.com Australia
PAVmed switches to new accounting firm post-acquisition By Investing.com - Investing.com South Africa
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - StreetInsider
Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection$60B Market Impact - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for PAVmed (NASDAQ:PAVM) Stock - The AM Reporter
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):